98%
921
2 minutes
20
Introduction: The Fränkel function regulator III appliance (FR-3) has been used to correct Class III malocclusions for many years; however, its treatment effectiveness is controversial. In this study, we aimed to assess the effectiveness of the FR-3 in treating patients with Class III malocclusion in the growth and development period.
Methods: Medline (via PubMed), Cochrane Central Register of Controlled Trials, Embase, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals, Scirus, Lilacs, Scopus, and World Health Organization International Clinical Trials Registry Platform were searched electronically. Relevant journals and reference lists of included studies were manually searched. The quality of the included studies was assessed with the Newcastle-Ottawa scale. The meta-analysis was carried out using RevMan (version 5.2; Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark).
Results: Seven high-quality cohort studies were included. The meta-analysis showed that SNA changes did not differ in the short (mean difference, 0.43°; 95% CI, -0.52°-1.39°) and long (mean difference, 0.37°; 95% CI, -0.29°-1.03°) terms. However, SNB changes significantly differed in the short (mean difference, -1.62°; 95% CI, -2.62° to -0.62°) and long (mean difference, -1.50°; 95% CI, -2.12° to -0.88°) terms. By contrast, MPA changes did not differ in the short term (mean difference, 0.55°; 95% CI, -0.74°-1.84°).
Conclusions: Clinical evidence suggests that the FR-3 might restrict mandibular growth but not stimulate forward movement of the maxilla. Further high-quality studies are necessary to confirm the effectiveness of the FR-3.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajodo.2014.04.017 | DOI Listing |
JACC Heart Fail
September 2025
German Center for Cardiovascular Research (DZHK); Heart Center Leipzig, Department of Internal Medicine/Cardiology, University of Leipzig, Leipzig, Germany.
Background: Residual congestion at hospital discharge after an episode of acute decompensated heart failure (ADHF) is associated with poor prognosis. There is no consensus on how optimal decongestion should be assessed.
Objectives: This study aims to determine whether decongestive therapy guided by ultrasound measurements of inferior vena cava (IVC) diameters leads to greater reductions in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels from baseline to hospital discharge as compared with decongestion treatment guided by clinical assessment alone.
Pol Merkur Lekarski
September 2025
LLC "ECOFARM", KYIV, UKRAINE.
Objective: Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID® at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system..
Patients And Methods: Materials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID® in women over the past decade.
J Mass Spectrom
October 2025
Department of Chemistry and Technology of Drugs, "Sapienza" University of Rome, Rome, Italy.
Ionic liquids (ILs) are a class of organic salts with melting points below 100°C. Owing to their unique chemical and physical properties, they are used as solvents and catalysts in various chemical transformations, progressively replacing common volatile organic solvents (VOCs) in green synthetic applications. However, their intrinsic ionic nature can restrict the use of mass spectrometric techniques to monitor the time progress of a reaction occurring in an IL medium, thus preventing one from following the formation of the reaction products or intercepting the reaction intermediates.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
September 2025
Department of Cardiology, Barts Heart Center, Barts Health NHS Trust, London, UK.
Background: Degeneration of surgical bioprosthetic aortic valves is increasingly common. Redo surgical aortic valve replacement carries substantial morbidity and mortality, particularly in elderly or high-risk patients. Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) has become an established alternative, though data on the performance of self-expanding Portico and Navitor valves remain limited.
View Article and Find Full Text PDFEur J Pharm Biopharm
September 2025
RaDes GmbH, Schnackenburgallee 114, 22525 Hamburg, Germany. Electronic address:
Polysorbate 20 (PS20) is one of the most commonly used non-ionic surfactants in cosmetics, pharmaceuticals and food products. Considered as biocompatible and non-irritating, it is further valued for its solubilising and protein stabilising properties. PS20 is manufactured through a multi-stage reaction of sorbitol with various fatty acids and ethylene oxide, resulting in a complex mixture of components with different molecular weights and polarity.
View Article and Find Full Text PDF